| [1] |
Ledford H, Tollefson J. Obama proposes cancer “moonshot” in State of the Union address[EB/OL].[2017-01-01].http:/ /www.nature.com/news/obama-proposes-cancer-moonshot-in-state-of-the-union-address-1.19155.
|
| [2] |
Prasad V. Perspective: The precision-oncology illusion[J]. Nature,2016,537(7619): S63.
|
| [3] |
Tannock IF,Hickman JA. Limits to personalized cancer medicine [J].N Engl J Med,2016,375(13):1289-1294.
|
| [4] |
Winer EP. The long and winding road: glancing back, but moving forward [EB/OL]. [2016-12-07]. https:/ /watch. ondemand. org/OnlinePlayer/files/WM01_1.PDF? ConfID=106.
|
| [5] |
Gradishar W, Salerno KE. NCCN guidelines update: breast cancer[J]. J Natl Compr Canc Netw,2016,14(5 Suppl):641-644.
|
| [6] |
Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer [J]. N Engl J Med,2016,375(8):717-729.
|
| [7] |
江泽飞, 许凤锐. 乳腺癌精准医学:热潮中的冷思考[J]. 中华外科杂志,2017,55(2):90-94.
|
| [8] |
李健斌, 江泽飞. 循环肿瘤细胞研究进展: 从计数到表型的转变[J].中华肿瘤杂志,2016,38(12):881-885.
|
| [9] |
Jiang ZF, Cristofanilli M, Shao ZM, et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative(CBCSG004): a multicenter, double-blind, prospective trial [J].Ann Oncol,2013,24(11):2766-2772.
|
| [10] |
Zhang S, Li L, Wang T, et al. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients[J].BMC Cancer,2016,16:526.
|
| [11] |
Wang T, Zhou J, Zhang S, et al. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients[J]. Clin Chim Acta,2016,458:23-29.
|
| [12] |
Ye Q, Qi F, Bian L, et al. Circulating-free DNA mutation associated with response of targeted therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. Chin Med J (Engl),2017,130(5):522-529.
|
| [13] |
叶青, 江泽飞. 循环肿瘤DNA 检测在乳腺癌诊断中的临床应用[J].中华癌症杂志,2016,26(11):23-27.
|
| [14] |
许凤锐,江泽飞. 精准医学时代肿瘤治疗决策:大数据与小随机[J]. 中华医学杂志,2017,97(4):241-243.
|
| [15] |
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence -what is it and what can it tell us? [J]. N Engl J Med,2016,375(23):2293-2297.
|
| [16] |
Matthijs G, Souche E, Alders M, et al. Guidelines for diagnostic nextgeneration sequencing [J]. Eur J Hum Genet,2016,24(1):2-5.
|
| [17] |
Nik-Zainal S, Davies H,Staaf J,et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences[J]. Nature, 2016,534(7605):47-54.
|
| [18] |
Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials[J]. J Clin Oncol,2015,33(25):2753-2762.
|